Literature DB >> 16421229

Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males.

Kent Doi1, Eisei Noiri, Akihide Nakao, Toshiro Fujita, Shuzo Kobayashi, Katsushi Tokunaga.   

Abstract

This study elucidates the genetic role of vascular endothelial growth factor (VEGF) as a predisposing factor for progression of chronic kidney disease. Single-nucleotide polymorphisms were genotyped and haplotype structures were determined in the 3' untranslated region (UTR) of VEGF gene, and the distribution of each haplotype in male patients with ESRD (n=101) and healthy male control subjects (n=189) was examined. The 936C/T and 1451C/T polymorphisms in the 3' UTR were in nearly absolute linkage disequilibrium, and haplotype analysis demonstrated that they were the primary responsible single-nucleotide polymorphisms. The distribution of the 936CC-1451CC genotype was significantly more frequent among patients with ESRD than among the age-matched healthy control subjects. In addition to case-control association study, the 936CC-1451CC genotype was also associated with significantly higher plasma VEGF levels in healthy individuals, but a significant association was found only in males, not in females. We also examined the effect of the 936C-1451C haplotype on mRNA stability. Consistent with the results of plasma VEGF levels, mRNA carrying 936C-1451C haplotype showed higher stability. The 936CC-1451CC genotype in the 3' UTR showed not only susceptibility for ESRD but also higher plasma VEGF levels and mRNA stability, indicating the contribution of VEGF to chronic kidney disease progression, especially in males.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421229     DOI: 10.1681/ASN.2005010094

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  15 in total

Review 1.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

2.  The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.

Authors:  Abdolrahim Nikzamir; Alireza Esteghamati; Amir Abbas Hammedian; Touraj Mahmoudi
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

Review 3.  Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.

Authors:  Susan A J Vaziri; Jenny Kim; Mahrukh K Ganapathi; Ram Ganapathi
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

4.  Neutrophil elastase contributes to acute lung injury induced by bilateral nephrectomy.

Authors:  Tomoko Ishii; Kent Doi; Koji Okamoto; Mitsuru Imamura; Makoto Dohi; Kazuhiko Yamamoto; Toshiro Fujita; Eisei Noiri
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

5.  Rs1982809 is a functional biomarker for the prognosis of severe post-traumatic sepsis and MODs.

Authors:  Lebin Gan; Chen Hu; Zhihong Deng; Hongxiang Lu; Jiali Sun; Guoxuan Peng; Jianxin Jiang; Ling Zeng; Jin Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

6.  Identification of KCNJ15 as a susceptibility gene in Asian patients with type 2 diabetes mellitus.

Authors:  Koji Okamoto; Naoko Iwasaki; Chisa Nishimura; Kent Doi; Eisei Noiri; Shinko Nakamura; Miho Takizawa; Makiko Ogata; Risa Fujimaki; Niels Grarup; Charlotta Pisinger; Knut Borch-Johnsen; Torsten Lauritzen; Annelli Sandbaek; Torben Hansen; Kazuki Yasuda; Haruhiko Osawa; Kishio Nanjo; Takashi Kadowaki; Masato Kasuga; Oluf Pedersen; Toshiro Fujita; Naoyuki Kamatani; Yasuhiko Iwamoto; Katsushi Tokunaga
Journal:  Am J Hum Genet       Date:  2010-01       Impact factor: 11.025

7.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

8.  Association of genetic variants with chronic kidney disease in Japanese individuals.

Authors:  Tetsuro Yoshida; Kimihiko Kato; Tetsuo Fujimaki; Kiyoshi Yokoi; Mitsutoshi Oguri; Sachiro Watanabe; Norifumi Metoki; Hidemi Yoshida; Kei Satoh; Yukitoshi Aoyagi; Yutaka Nishigaki; Masashi Tanaka; Yoshinori Nozawa; Genjiro Kimura; Yoshiji Yamada
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

9.  Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.

Authors:  Tetsuro Yoshida; Kimihiko Kato; Kiyoshi Yokoi; Mitsutoshi Oguri; Sachiro Watanabe; Norifumi Metoki; Hidemi Yoshida; Kei Satoh; Yukitoshi Aoyagi; Yoshinori Nozawa; Yoshiji Yamada
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

Review 10.  The role of vascular endothelial growth factor a polymorphisms in breast cancer.

Authors:  Doonyapat Sa-Nguanraksa; Pornchai O-Charoenrat
Journal:  Int J Mol Sci       Date:  2012-11-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.